Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NeoStem’s (AMEX: NBS) Progenitor Cell Therapy announce a Manufacturing Agreement

ImmunoCellular Therapeutics (OTC BB: IMUC) has added NBS’s subsidiary, Progenitor Cell Therapy (PCT) as a 2nd manufacturing site to produce ICT-107 for P2 trial, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. 
  • As part of this agreement, PCT will transfer and qualify the cGMP manufacturing process for ICT-107 at PCT’s West Coast facility inMountain View, Ca for use in IMUC’s US based P2 clinical trial, as well as subsequent manufacturing to support future trials and development efforts.

The Bottom Line: NBS … Revenue …  major risk mitigation (forIMUC) agreement validates quality and quantity in conducting IMUC’s P2 study of ICT-107 by having 2 manufacturing sites. PCT has significant experience in developing and manufacturing patient-specific products and capabilities for supporting this manufacturing for a P2 trial,  a possible …P3 trial and … potential commercialization. PCT’s competencies are in autologous cell therapies, cell manufacturing, cell processing and delivery.